


SARS-CoV-2 Sequencing Update 23 September 2022



Supported by the DSI and the SA MRC
Msomi N. Mlisana K. et al. Lancet Microbe 2020

The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 23 September 2022 at 10h50




Data license: <https://www.gisaid.org/registration/terms-of-use/>

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. *Global Challenges*, 1:33-46. DOI: 10.1002/gch2.1018 PMID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. *EuroSurveillance*, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMID: PMC5388101

Number of South African genomes deposited on GISAID, by specimen collection week, 2020 – 2022


(N=45 432*)




*This represents the cleaned, de-duplicated dataset of unique **National and Pneumonia Surveillance** sequences. This dataset will be used for all further figures.

GISAID genomes vs total cases, 2020 – 2022 (N=45 432)


Provincial breakdown of genomes deposited into GISAID



Proportion of total cases versus proportion of total genomes



Number and percentage of clades by epiweek in South Africa, 2021 – 2022 (38 603*)




Sequencing data ending epi week 36 (ending 10 Sep 2022)

Currently in epi week 38 (ending 24 Sep 2022)

*Excludes sequences missing collection dates, as well as those collected January 1st and 2nd 2021 as they are part of epiweek 53 of 2020.


Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in June – August 2022

June (N=1023)




Total Omicron in June: 1009 (98.6%)

July (N=464)



Total Omicron in July: 461 (99.4%)

August (N=207)




Total Omicron in August: 203 (98.1%)





Detection Rates: Beta, Delta, C.1.2 and Omicron

Detection rates of variants being monitored in South Africa




*Bars represent percentage prevalence of variant for the month; total number sequences collected for the month are given below the bar


South Africa, 2021-2022, n = 38 603*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*Excludes sequences missing collection dates, as well as those collected January 1st and 2nd 2021 as they are part of epiweek 53 of 2020.

Eastern Cape Province, 2021-2022, n = 3025


Genomes added since last report: 1*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Free State Province, 2021-2022, n = 1632


Genomes added since last report: 2*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Gauteng Province, 2021-2022, n = 10 662


Genomes added since last report: 7*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

KwaZulu-Natal Province, 2021-2022, n = 4306


Genomes added since last report: 62*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Limpopo Province, 2021-2022, n = 2649


Genomes added since last report: 1*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Mpumalanga Province, 2021-2022, n = 3001


Genomes added since last report: 81*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Northern Cape Province, 2021-2022, n = 1959


Genomes added since last report: 1*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

North West Province, 2021-2022, n = 2266


Genomes added since last report: 2*



Clade key (bar graph)





Weekly percentage testing positive key (line graph)




*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Western Cape Province, 2021-2022, n = 9091


Genomes added since last report: 4*



Clade key (bar graph)



Weekly percentage testing positive key (line graph)



*May include genomes from 2020 which are not pictured here and are not included in the slide total.

Summary

- **Sequencing update**

- All provinces have sequences for June and July. Only the North West does not have August data. Gauteng and the Western Cape have September data.

- **Variant of Concern Omicron in South Africa**

- Omicron continued to dominate in June (99%), July (99%), August (98%), and currently makes up 100% of September sequences although numbers are small.
- Omicron BA.5 was dominant in July (68%) and August (71%), and makes up 83% of September data.
- BA.2.12.1 was detected in South Africa at low prevalence in May, June and July (<1%)
- BA.2.75 has only been detected once in South Africa in July (n=1).


- **N=14 sequences with novel mutational profile**

- The New1 cluster (n = 10, predominantly from Gauteng) has been designated “XAY”, and the New2 cluster (n = 4, Limpopo) has been designated “XBA”¹.
- N=1 new XAY has been detected since the previous report, collected 1 August in Mpumalanga.

- Low frequency of previously circulating variants such as Delta not detected since July.

¹ <https://github.com/cov-lineages/pango-designation/issues/844>

Spike protein mutation* profile of Variants of Interest and Concern




- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
 - Including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
 - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape



*Only mutations present in Omicron, Delta, or the new SGTP sequences are pictured

BA.4 and BA.5 spike mutations



SP
NTD
RBD
RBM
S1
S2
HR1
HR2



BA.4 whole genome mutation prevalence over time




BA.5 whole genome mutation prevalence over time





NGS-SA

Network for Genomic Surveillance in South Africa



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA



EDCTP

This project (RIA2020EF-3030) is part of the EDCTP2 programme supported by the European Union"



University of Stellenbosch & NHLS Tygerberg Virology



Susan Engelbrecht
Wolfgang Preiser
Gert van Zyl
Tongai Maponga
Bronwyn Kleinhans
Shannon Wilson
Karabo Phadu
Tania Stander
Kamela Mahlakwane
Mathilda Claassen
Diagnostic laboratory staff

UKZN-Inkosi Albert Luthuli Central Hospital



Dr Khanyi Msomi
Dr Kerusha Govender
Dr Pravi Moodley
Dr Aabida Khan
Dr Lili Gounder
Dr Kerri Francois
Dr Cherise Naicker
Dr Joedene Chetty

Dr Neli Ngcaba
Dr Tshepiso Mosito
Mr Malcolm Ellapen
Mr Kubendran Reddy
The COVID-19 Bench team

University of KwaZulu-Natal & Africa Health Research Institute



KRISP at UKZN:
Tulio de Oliveira
Richard Lessels
Houriiyah Tegally
Eduan Wilkinson
Jennifer Giandhari
Sureshnee Pillay
Emmanuel James San



AHRI
Alex Sigal
Sandile Cele
Willem Hanekom

University of Cape Town, NHLS & Western Cape Government



NHLS-UCT
Carolyn Williamson
Nei-yuan Hsiao
Diana Hardie
Kruger Marais
Stephen Korsman
Ziyaad Valley-Omar

WCG-UCT
Mary-Anne Davies
Hannah Hussey
Andrew Boule
Masudah Paleker
Theuns Jacobs
Erna Morden

NHLS Greenpoint
Annabel Enoch

This project has received funding from the European Union's Horizon Europe Research and Innovation Actions under grant No. 101046041



Zoonotic arbo and respiratory virus program Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria



ZARV research program/UP
Marietjie Venter (Head: ZARV)
Adriano Mendes (Postdoc)
Amy Strydom (Postdoc)
Michaela Davis (MSc, intern medical scientist)
Carien van Niekerk



NHLS Tshwane
Prof Simnikiwe Mayaphi (HOD)

Funders:
GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA)
G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

National Institute for Communicable Diseases



Centre for Respiratory Diseases & Meningitis

Anne von Gottberg
Thabo Mohale
Daniel Amoako
Josie Everatt
Boitshoko Mahlangu
Noxolo Ntuli
Anele Mnguni
Amelia Buys
Cardia Fourie
Noluthando Duma
Linda de Gouveia
Jackie Kleynhans
Nicole Wolter
Sibongile Walaza
Mignon du Plessis
Stefano Tempia
Mvuyo Makhasi
Cheryl Cohen

Centre for HIV and STIs

Jinal Bhiman
Cathrine Scheepers
Constantinos Kurt Wibmer
Thandeka Moyo
Tandile Hermanus
Frances Ayres
Zanele Molaudzi
Bronwen Lambson
Tandile Hermanus
Mashudu Madzivhandila
Prudence Kgagudi
Brent Oosthuysen
Penny Moore
Lynn Morris

NICD Groups

NICD COVID-19 response team
NICD SARS-CoV-2 Sequencing Group

Sequencing Core Facility

Zamantungwa Khumalo
Annie Chan
Morne du Plessis
Stanford Kwenda
Phillip Senzo Mtshali
Mushal Allam
Florah Mnyameni
Arshad Ismail



University of the Free State



UFS
Dominique Goedhals
Armand Bester
Martin Myaga
Peter Mwangi
Emmanuel Ogunbayo
Milton Mogotsi
Makgotso Maotoana
Lutfiyya Mohamed



NHLS Division of Virology
Sabeehah Vawda
Felicity Burt
Thokozani Mkhize
Diagnostic laboratory staff



UCT, IDM and CIDRI-Africa

Deelan Doolabh
Arash Iranzadeh
Lynn Tyers
Innocent Mudau
Nokuzola Mbhele
Fezokuhle Khumalo
Thabang Serake
Bruna Galvão
Arghavan Alisoltani
(U. California)

Robert Wilkinson
Darren Martin
Nicola Mulder
Wendy Burgers
Ntobeko Ntusi
Rageema Joseph
Sean Wasserman
Linda Boloko





Additional support and collaborators



NHLS

Koeleka Mlisana
Zinhle Makatini
Eugene Elliot
Florette K. Treurnicht
Kathleen Subramoney
Oluwakemi Laguda-Akingba
Shareef Abrahams
Greta Hoyland
Gloria Selabe
Elias Bereda
Jeannette Wadula



Hyrax Biosciences

Simon Travers

Cape Town HVTN Laboratory

Erica Anderson-Nissen
Anneta Naidoo

Ndlovu Research

Hugo Tempelman
CJ Umunnakwe



Lancet

Allison J. Glass
Raquel Viana

Ampath

Terry Marshall
Cindy van Deventer
Eddie Silberbauer

Pathcare Vermaak

Andries Dreyer
Howard Newman
Riaan Writes
Marianne Wolfaardt
Warren Lowman

Bridge-the-Gap

Raymond Rott

Cytespace Africa Laboratories

Christa Viljoen

ARC-OVI

Lia Rotherham

CAPRISA

Salim Abdool Karim
Nigel Garret

UKZN - Big Data

Francesco Petruccione
Ilya Sinayskiy

University of Oxford

José Lourenço

FioCruz, Brazil

Vagner Fonseca
Marta Giovanetti
Luiz Carlos Junior Alcantara

Africa CDC

John Nkengasong
Sofonias Tessema

Netcare:

Richard Friedland
Craig Murphy
Caroline Maslo
Liza Sitharam

DSI


Glaudina Loots

SA MRC

Glenda Gray



South African genomes submitted per submitting lab, 2020 - 2022 (N=45 432)



NGS-SA Labs

CERI: Centre for Epidemic Response and Innovation
KRISP: KZN Research Innovation and Sequencing Platform
NDLOVU: Ndlovu Research Laboratories
NICD: National Institute for Communicable Diseases
NHLS: National Health Laboratory Service
SU: Stellenbosch University
UCT: University of Cape Town
UFS: University of the Free State
UP: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.

Currently circulating Variants of Concern (VOC)

WHO label	Pango lineage [•]	GISAID clade	Nextstrain clade	Additional amino acid changes monitored [°]	Earliest documented samples	Date of designation
Omicron*	B.1.1.529	GR/484A	21K, 21L, 21M, 22A, 22B, 22C, 22D	+S:R346K +S:L452X +S:F486V	Multiple countries, Nov-2021	VUM: 24-Nov-2021 VOC: 26-Nov-2021

* Includes BA.1, BA.2, BA.3, BA.4, BA.5 and descendent lineages. It also includes BA.1/BA.2 circulating recombinant forms such as XE. WHO emphasizes that these descendant lineages should be monitored as distinct lineages by public health authorities and comparative assessments of their virus characteristics should be undertaken.

[•] Only found in a subset of sequences

Previously circulating Variants of Concern

WHO label	Pango lineage•	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY	20I (V1)	United Kingdom, Sep-2020	VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022
Beta	B.1.351	GH/501Y.V2	20H (V2)	South Africa, May-2020	VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022
Gamma	P.1	GR/501Y.V3	20J (V3)	Brazil, Nov-2020	VOC: 11-Jan-2021 Previous VOC: 09-Mar-2022
Delta	B.1.617.2	G/478K.V1	21A, 21I, 21J	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021 Previous VOC: 7-Jun-2022

• Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> accessed 12 August 2022

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) **OR**
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥ 14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥ 90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of “unusual” cases (e.g., in terms of disease presentation, patient groups affected, etc.)